drugset / Trial / NCT04591431

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

NCT04591431 ↗

Phase 2 Unknown 400 enrolled Fondazione per la Medicina Personalizzata
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, prospective, multicenter, Proof of Concept, Phase II clinical trial Study. The main objective of the study is to evaluate the efficacy (meant as overall response rate ORR) of TT (targeted Therapy) vs SoC (standard of Care) in patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed at least 1 line of treatment and no more than 2 as defined by the current version of the AIOM (Italian Association of Medical Oncology) guidelines. Patients are included if surgery is contraindicated.

Timeline

Start
2020-10-07
Primary completion
2024-12
Completion
2025-06

Outcome

Met primary endpoint

paper TT achieved a significantly higher ORR (17.5% versus 10%; P = 0.0294) PMID 41023484 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alectinib Small molecule — —
Subject Alpelisib Small molecule — —
Subject Atezolizumab Monoclonal antibody — —
Subject Brigatinib Small molecule — —
Subject Cobimetinib Small molecule — —
Subject Entrectinib Small molecule — —
Subject Erlotinib Small molecule — —
Subject Everolimus Small molecule — —
Subject Ipatasertib Small molecule — —
Subject Ipilimumab Monoclonal antibody — —
Subject Itacitinib Small molecule — —
Subject Lapatinib Small molecule — —
Subject Nivolumab Monoclonal antibody — —
Subject Palbociclib Small molecule — —
Subject Pemigatinib Small molecule — —
Subject Pertuzumab Monoclonal antibody — —
Subject Ponatinib Small molecule — —
Subject Pralsetinib Small molecule — —
Subject Selpercatinib Small molecule — —
Subject Talazoparib Small molecule — —
Subject Tepotinib Small molecule — —
Subject Trastuzumab Monoclonal antibody — —
Subject Trastuzumab emtansine Other / unclassified — —
Subject Vemurafenib Small molecule — —
Subject Vismogedib Unknown — —